TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10894101
Drug: Becloforte (250-1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Becloforte (250-1000 microg per dose; cumulative dose 2000 microg)
Study: 2066844
Drug: Clindamycin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (20 mg/kg per day, three times a day for 10 days)
Study: 2066844
Drug: Penicillin plus
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin plus rifampin (benzathine penicillin intramuscularly and rifampin 20 mg/kg per day, twice a day for 4 days)
Study: 7034680
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous dose of gentamicin sulfate and clindamycin phosphate
Study: 20427960
Drug: Prevention strategies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prevention strategies for cardiorenal syndromes, including identification and amelioration of precipitating factors, optimal management of chronic heart and kidney diseases, and multimodality therapies for end-organ protection.
Study: 7837862
Drug: Reduced-osmolarity ORS
Normalized name: Orserdu
DrugBank: Elacestrant (DB06374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-osmolarity ORS (224 mmol/L)
Study: 2351319
Drug: Cisplatin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (100 mg/m2 iv bolus) and 5-fluorouracil (1000 mg/m2/day for 4 days) with allopurinol (900 mg orally, starting 5 days before 5-fluorouracil)
Study: 22883712
Drug: Clopidogrel plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel plus aspirin (dual treatment) for seven days
Study: 22883712
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (monotherapy) for seven days
Study: 21872933
Drug: Conventional management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional management (CM) - treatment only if threshold ROP developed
Study: 11172346
Drug: PEG(40kd) IFN
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG(40kd) IFN alpha‐2a 45 microg once weekly
Study: 11172346
Drug: PEG(40kd) IFN
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG(40kd) IFN alpha‐2a 90 microg once weekly
Study: 11172346
Drug: PEG(40kd) IFN
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG(40kd) IFN alpha‐2a 180 microg once weekly
Study: 11172346
Drug: PEG(40kd) IFN
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG(40kd) IFN alpha‐2a 270 microg once weekly
Study: 11172346
Drug: IFN alpha‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN alpha‐2a 3 MIU 3 times weekly
Study: 9426760
Drug: Oxybutynin 5
Normalized name: oxyBUTYnin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin 5 mg three times daily
Study: 21251076
Drug: Chlorhexidine gel
Normalized name: chlorhexidine Oral Gel
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gel (0.5%)
Study: 21796066
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 5 mg (single intravenous infusion)
Study: 21796066
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg (daily oral for 6 months)
Study: 16717032
Drug: Ximelagatran (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran (2 x 24 mg)
Study: 7050710
Drug: Aspirin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (0.5 g given three times a day)
Study: 30390203
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg/Valsartan 160 mg (A/V)
Study: 30390203
Drug: Nebivolol 5
Normalized name: nebivolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 5 mg/Valsartan 160 mg (N/V)
Study: 26930583
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg artesunate and 135 mg amodiaquine fixed dose formulation
Study: 23903900
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 0.2 % ropivacaine at 4 ml/h with a bolus of 0 ml
Study: 23903900
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 0.2 % ropivacaine at 0 ml/h with a bolus of 4 ml
Study: 20336047
Drug: Reamberin in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reamberin in combined treatment
Study: 18507525
Drug: Needle-free injection
Normalized name: Stratis Needle-Free Injection Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle-free injection device (NFID)
Study: 16340384
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) at 500 mg twice daily for 2 months, then increased to 1000 mg twice daily for 4 months
Study: 6754510
Drug: Tolciclate 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolciclate 1% cream and lotion applied twice a day for about 3 weeks
Study: 6754510
Drug: Clotrimazole 1%
Normalized name: CLOTRIMAZOLE 1% LOTION
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clotrimazole 1% cream and lotion applied twice a day for about 3 weeks
Study: 28672098
Drug: Inhaled Budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Budesonide 1000 μg/dose
Study: 27269956
Drug: Ibudilast (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibudilast (20 mg twice daily followed by 50 mg twice daily)
Study: 22749817
Drug: HIFU ablation
Normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIFU ablation with 1 mL of iodized oil
Study: 14597886
Drug: Nuclear medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nuclear medicine studies and stress echocardiography
Study: 10360854
Drug: Propofol (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (0.75 mg/kg for verbal command response)
Study: 10360854
Drug: Propofol (1.28
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1.28 mg/kg for tetanic stimulus response)
Study: 10360854
Drug: Propofol (1.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1.01 mg/kg for verbal command response)
Study: 10360854
Drug: Propofol (1.76
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1.76 mg/kg for tetanic stimulus response)
Study: 10360854
Drug: Propofol (0.98
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (0.98 mg/kg for verbal command response)
Study: 10360854
Drug: Propofol (1.89
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1.89 mg/kg for tetanic stimulus response)
Study: 1826213
Drug: celiprolol 400
Normalized name: celiprolol 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: celiprolol 400 mg/day
Study: 27163699
Drug: Taurine supplementation
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurine supplementation (2.0 g, 3 times per day for 14 days)
Study: 27163699
Drug: Placebo (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2.0 g, 3 times per day for 14 days)
Study: 23032585
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% saline solution) injection
Study: 9584539
Drug: Special intervention
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Special intervention (psychiatric evaluation plus 1 to 7 sessions of behavioral therapy)
Study: 2759361
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of 300 ml of water to a meal
Study: 29908359
Drug: rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 10 mg daily (n = 72)
Study: 24171979
Drug: Hemocoagulase solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemocoagulase solution
Study: 19484759
Drug: Piperacillin/tazobactam (PIP/TAZO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam (PIP/TAZO) 80 mg/kg piperacillin/10 mg/kg tazobactam every 6 hr
Study: 19484759
Drug: Cefepime (CEF)
DrugBank: Cefepime (DB01413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefepime (CEF) 50 mg/kg every 8 hr
Study: 17121552
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine (2.0 mg.kg(‐1))
Study: 10989266
Drug: MDMA (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (1.5 mg/kg p.o.) with ketanserin (50 mg p.o.)
Study: 10989266
Drug: MDMA (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (1.5 mg/kg p.o.) alone
Study: 9077073
Drug: LTB*-combined vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTB*-combined vaccine
Study: 7524759
Drug: 30 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 micrograms of recombinant G-CSF per day
Study: 7524759
Drug: 300 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 micrograms of recombinant G-CSF per day
Study: 2884855
Drug: Doxazosin, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin, administered once daily
Study: 2884855
Drug: Prazosin, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin, administered twice daily
Study: 31782167
Drug: Routine care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine care (daily pyridoxine [50 mg] and psychoeducation)
Study: 28608739
Drug: AM-101 0.87
Approvals — FDA: no, EMA: no, PMDA: no
Description: AM-101 0.87 mg/mL
Study: 23519139
Drug: Factor IX
Normalized name: Factor IX
DrugBank: Coagulation Factor IX Human (DB13152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Factor IX Complex (mean dose 35 units/kg)
Study: 19544758
Drug: Online treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online treatment
Study: 8217239
Drug: Radiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy with weekly 5-FU (600 mg/m2)
Study: 26933811
Drug: Low-dose tacrolimus
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tacrolimus (0.04-0.05 mg/kg/day) + donor-derived mesenchymal stem cells (MSCs)
Study: 26933811
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose tacrolimus (0.07-0.08 mg/kg/day)
Study: 26933811
Drug: Low-dose tacrolimus
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tacrolimus + MSCs
Study: 26933811
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose tacrolimus
Study: 24935932
Drug: DPP4 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DPP4 inhibitor sitagliptin
Study: 21825083
Drug: VX-809 100
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VX-809 100 mg
Study: 21825083
Drug: VX-809 200
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VX-809 200 mg
Study: 18523884
Drug: Heat treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat treatment at 40 degrees C for 2 hours
Study: 15853214
Drug: YM 294
Approvals — FDA: no, EMA: no, PMDA: no
Description: YM 294 (rhlL-11) at a dose of 50 microg/kg
Study: 15853214
Drug: Non-treatment observation
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment observation group
Study: 8864421
Drug: ANP (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANP (10 ng kg‐1 min‐1) during ANG II infusion
Study: 8864421
Drug: ANP (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANP (10 ng kg‐1 min‐1) during NA infusion
Study: 1379107
Drug: Finasteride 10
Normalized name: finasteride 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 10 mg/day
Study: 7689971
Drug: Finasteride 5
Normalized name: finasteride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 5 mg/day (3 years therapy)
Study: 3780288
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg diazepam in conventional tablet form on the morning of operation
Study: 3780288
Drug: Sustained-release diazepam
Normalized name: diazepam Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release diazepam the night before surgery
Study: 27287784
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard pharmacotherapy)
Study: 22699824
Drug: BI 2536
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 2536 200 mg on day 1
Study: 22699824
Drug: BI 2536
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 2536 60 mg on days 1-3
Study: 9888075
Drug: Nonpreserved ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpreserved ketorolac tromethamine 0.5% ophthalmic solution, 4 times daily for 3 days or until no ocular pain
Study: 9438895
Drug: Granisetron 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 1.0 mg
Study: 27257981
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose intraarticular injection of 4 ml lightly cross‐linking sodium hyaluronate (Monovisc)
Study: 27257981
Drug: Three consecutive
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three consecutive intraarticular injections of 2.5 ml standard linear sodium hyaluronate (Adant) with one week intervals
Study: 24366001
Drug: Levobupivacaine (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine (Group L)
Study: 23469594
Drug: Mesalazine Enteric-coated
Normalized name: mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalazine Enteric-coated Tablet (MECT)
Study: 18034666
Drug: Voriconazole 400
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Voriconazole 400 mg twice daily on the first day and 200 mg twice daily on the second day, followed by 50 mg diclofenac 1 h after the last dose of voriconazole
Study: 18034666
Drug: Control phase
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control phase with a single 50-mg oral dose of diclofenac
Study: 1980733
Drug: Inhaled Magnesium
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Magnesium sulfate (MgS04)
Study: 1980733
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MgS04 and salbutamol
Study: 359108
Drug: Butorphanol tartrate
Normalized name: Butorphanol Tartrate
DrugBank: Butorphanol (DB00611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Butorphanol tartrate (mean dose 2.0 mg)
Study: 359108
Drug: Butorphanol tartrate
Normalized name: Butorphanol Tartrate
DrugBank: Butorphanol (DB00611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Butorphanol tartrate (average 4.6 mg per patient)
Study: 359108
Drug: Morphine sulphate
Normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulphate (average 22.8 mg per patient)
Study: 27986461
Drug: Hourly titrated-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hourly titrated-dose oral misoprostol solution (20 μg hourly, increased to 40 μg and then to 60 μg)
Study: 27986461
Drug: 2-hourly static-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-hourly static-dose oral misoprostol solution (25 μg every 2 hours)
Study: 27986461
Drug: Hourly titrated-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hourly titrated-dose oral misoprostol solution
Study: 27986461
Drug: 2-hourly static-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-hourly static-dose oral misoprostol solution
Study: 23315029
Drug: Olaparib 10
Normalized name: olaparib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib 10 mg
Study: 23315029
Drug: Olaparib 30
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 30 mg
Study: 23315029
Drug: Olaparib 100
Normalized name: olaparib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib 100 mg
Study: 23315029
Drug: Olaparib 200
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 200 mg
Study: 23315029
Drug: Olaparib 400
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 400 mg
Study: 27422301
Drug: Olaparib (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (all doses)
Study: 17721555
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml bolus doses of 0.1% bupivacaine with butorphanol 2 mg (Group A)
Study: 17721555
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of 0.25% plain bupivacaine (Group B)
Study: 7933501
Drug: Total Intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Intravenous Anesthesia (TIVA) with vecuronium 0.1 mg.kg‐1 and edrophonium 0.75 mg.kg‐1
Study: 7933501
Drug: Neuroleptanalgesia (NLA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptanalgesia (NLA) with vecuronium 0.1 mg.kg‐1 and edrophonium 0.75 mg.kg‐1
Study: 7933501
Drug: Sevoflurane Anesthesia
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane Anesthesia (SA) with vecuronium 0.1 mg.kg‐1 and edrophonium 0.75 mg.kg‐1
Study: 28120486
Drug: BI 409306
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 409306 (25-, 50-, 100-, and 200-mg single dose)
Study: 23734921
Drug: Cognitive and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive and interpersonal group therapy
Study: 18796160
Drug: Pregabalin 600
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 600 mg/d (300 mg BID)
Study: 17022857
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment, titrated to 0.012 mg/kg/day
Study: 11087880
Drug: Intrathecal methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal methylprednisolone and lidocaine (3 ml of 3 percent lidocaine with 60 mg of methylprednisolone acetate, 89 patients)
Study: 11087880
Drug: Lidocaine alone
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine alone (3 ml of 3 percent lidocaine, 91 patients)
Study: 11087880
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (90 patients)
Study: 1582300
Drug: 12 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 micrograms formoterol DP capsules
Study: 1582300
Drug: 24 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 micrograms formoterol DP capsules
Study: 1582300
Drug: 48 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48 micrograms formoterol DP capsules
Study: 4075796
Drug: Continuous vitamin
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous vitamin supplementation (10 mg vitamin B6 daily or twice the dose daily for 7 non-hormone days)
Study: 4075796
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral contraceptive treatment
Study: 31760846
Drug: Topical cedar
Normalized name: Cedar oil
DrugBank: Cedar oil (DB10917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cedar solution plus clindamycin 1%
Study: 31760846
Drug: Topical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical placebo plus 1% clindamycin
Study: 29381544
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL of small‐particle hyaluronic acid with lidocaine (SP‐HAL) microaliquots
Study: 29381544
Drug: Sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection of sterile normal saline
Study: 29381544
Drug: SP‐HAL treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP‐HAL treatment
Study: 22117732
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of clinical parameters between turned and TiUnite implants
Study: 19174782
Drug: Etoricoxib (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib (60 or 90 mg daily)
Study: 17701770
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT), mean duration of exposure 8.3 years, 31% exposed for >=10 years
Study: 17701770
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) - route of administration
Study: 17701770
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) - type of HRT
Study: 11936169
Drug: Incidental exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incidental exposure to music in daily routine
Study: 27422026
Drug: Biomarker-guided recommendation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biomarker-guided recommendation on antibiotics (BAL fluid tested for IL-1β and IL-8 in addition to routine microbiology testing)
Study: 27422026
Drug: Routine use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine use of antibiotics (BAL undergoes routine microbiology testing only)
Study: 27422026
Drug: Biomarker-guided recommendation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biomarker-guided recommendation on antibiotics
Study: 25117806
Drug: Pre-filled blister
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-filled blister packaging labeled for daily use with reminders (MeadWestvaco Corporation's pre-filled DosePak® containing standard doses of statins)